<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7531</journal-id>
<journal-title><![CDATA[Revista Cubana de Pediatría]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cubana Pediatr]]></abbrev-journal-title>
<issn>0034-7531</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-75312011000200012</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Radioterapia de intensidad modulada en el tratamiento de tumores en pediatría, primeros casos en Cuba: first cases in Cuba]]></article-title>
<article-title xml:lang="en"><![CDATA[Intensity Modulated Radiotherapy in treatment of tumors in children]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alert Silva]]></surname>
<given-names><![CDATA[José]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Chon Rivas]]></surname>
<given-names><![CDATA[Ivonne]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Nápoles Morales]]></surname>
<given-names><![CDATA[Misleidy]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez Peña]]></surname>
<given-names><![CDATA[Lourdes]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Larrinaga Cortina]]></surname>
<given-names><![CDATA[Eduardo]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alfonso Laguardia]]></surname>
<given-names><![CDATA[Rodolfo]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Silvestre Patayo]]></surname>
<given-names><![CDATA[Ileana]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García Yip]]></surname>
<given-names><![CDATA[Fernando]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lara Mas]]></surname>
<given-names><![CDATA[Elier]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Diaz Moreno]]></surname>
<given-names><![CDATA[Rogelio]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Instituto Nacional de Oncología y Radiobiología Departamento de Radioterapia ]]></institution>
<addr-line><![CDATA[La Habana ]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2011</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2011</year>
</pub-date>
<volume>83</volume>
<numero>2</numero>
<fpage>207</fpage>
<lpage>214</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0034-75312011000200012&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0034-75312011000200012&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0034-75312011000200012&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[INTRODUCCIÓN. La radioterapia de intensidad modulada (IMRT) constituye una técnica de alta precisión basada en la definición volumétrica tridimensional de la anatomía del tumor y de los órganos críticos o en riesgo. Con el objetivo de asegurar la posibilidad de aplicar la IMRT en Cuba, en casos seleccionados de tumores en niños y adolescentes, se instrumentó un proyecto de investigación cuyos resultados se documentan en este informe. MÉTODOS. Se realizaron las primeras irradiaciones con IMRT en niños y adolescentes cubanos, con edades entre 6 y 18 años. La técnica empleada es la basada en aperturas geométricas y optimización inversa. Las irradiaciones fueron realizadas con un acelerador lineal con fotones de 6 MV, con colimador multiláminas. Las dosis de radiaciones administradas variaron según el tipo de tumor, y de acuerdo con las normas de radioterapia y la presencia de órganos críticos. Todos los pacientes fueron evaluados semanalmente, con controles radiológicos mediante placas portales electrónicas. RESULTADOS. Los pacientes irradiados (5) tenían los tumores siguientes: linfoma no-Hodgking del seno maxilar (1), glioma del tallo cerebral (1), linfoma no-Hodgking abdominal (1), condrosarcoma mesenquimatoso parameníngeo (1) y hemangiopericitoma parameníngeo (1). Las dosis de irradiación recibidas variaron entre 24 y 62 Gy. Fueron empleados entre 5 y 8 campos, con variaciones entre 10 y 20 segmentos. CONCLUSIONES. Se realizaron en Cuba las primeras irradiaciones con IMRT en niños y adolescentes, y se debe continuar extendiendo su empleo en aquellos casos donde su utilidad sea mayor.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[INTRODUCTION. The intensity modulated radiotherapy (IMRT) is a high performance technique based on the three-dimensional volumetric definition of tumor anatomy and of critical organs or at risk. To assure the possibility to apply the IMRT in Cuba in selected cases of tumors in children and adolescents, authors designed a research project whose results are documented in present report. METHODS. The first irradiations with IMRT in Cuban children and adolescents aged between 6 -18 were carried out. The technique used is that based on the geometric openings and inverse optimization. Irradiations were applied using a linear accelerator with 6 MV photons, with multileaf collimator. Doses administered varied according to the type of tumor, the radiotherapy standards and the presence of critical organs. All patients were assessed weekly with radiologic controls using electronic portal plates. RESULTS. Irradiated patients (5) had the following tumors: non-Hodgkin lymphoma of maxillary sinus (1), brain stem glioma (1), non-Hodgkin abdominal lymphoma (1), parameningeal mesenchymatous chondrosarcoma (1) and parameningeal hemangiopericytoma (1). Doses of radiation applied varied between 24 and 62 Gy. Between 5 and 8 fields were used with variations among 10 and 20 segments. CONCLUSIONS. In Cuba the first irradiations with IMRT in children and adolescents and its use must to be spreading to those cases where its usefulness is greater.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Radioterapia de intensidad modulada]]></kwd>
<kwd lng="es"><![CDATA[IMRT]]></kwd>
<kwd lng="es"><![CDATA[tumores]]></kwd>
<kwd lng="es"><![CDATA[pediatría]]></kwd>
<kwd lng="es"><![CDATA[Cuba]]></kwd>
<kwd lng="en"><![CDATA[Modulated intensity radiotherapy]]></kwd>
<kwd lng="en"><![CDATA[MIRT]]></kwd>
<kwd lng="en"><![CDATA[tumor]]></kwd>
<kwd lng="en"><![CDATA[Pediatrics]]></kwd>
<kwd lng="en"><![CDATA[Cuba]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <div align="right"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">    <B>COLABORACI&Oacute;N ESPECIAL </B></font> </div>     <P ALIGN="left"><font size="2"><b><font size="4" face="Verdana, Arial, Helvetica, sans-serif">    <br>       <br>       <br>   Radioterapia de intensidad modulada en el tratamiento de tumores en pediatr&iacute;a,    primeros casos en Cuba </font>   </b> </font>     <P ALIGN="left">    <br>       <br>   <font size="2"><b><font size="3" face="Verdana, Arial, Helvetica, sans-serif">Intensity Modulated Radiotherapy in treatment of tumors in children: first cases in Cuba   </font>   </b></font>      <P ALIGN="left">    <br>       ]]></body>
<body><![CDATA[<br>         <br>         <br>   <font size="2"><b><font face="Verdana, Arial, Helvetica, sans-serif">Jos&eacute; Alert    Silva,<SUP>I</SUP> Ivonne Chon Rivas,<SUP>II</SUP> Misleidy N&aacute;poles    Morales,<SUP>III</SUP> Lourdes P&eacute;rez    Pe&ntilde;a,<SUP>IV</SUP> Eduardo Larrinaga    Cortina,<SUP>V</SUP> Rodolfo Alfonso    Laguardia,<SUP>VI</SUP> Ileana Silvestre    Patayo,<SUP>VII</SUP> Fernando Garc&iacute;a    Yip,<SUP>VIII</SUP> Elier Lara Mas,<SUP>IX</SUP> Rogelio Diaz Moreno <SUP>X</SUP></font></b></font>     <P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><SUP>I</SUP>Especialista    de II Grado en Oncolog&iacute;a. Profesor Auxiliar. Investigador Auxiliar. Departamento    de Radioterapia, Instituto Nacional de Oncolog&iacute;a y Radiobiolog&iacute;a.    La Habana, Cuba. </font>     <br>   <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><SUP>II</SUP>Especialista    de II Grado en Oncolog&iacute;a. Profesor Auxiliar. Investigador Agregado. Departamento    de Radioterapia, Instituto Nacional de Oncolog&iacute;a y Radiobiolog&iacute;a.    La Habana, Cuba. </font>     <br>   <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><SUP>III</SUP>Especialista    de II Grado en Oncolog&iacute;a. Profesor Auxiliar. Investigador Agregado. Departamento    de Radioterapia, Instituto Nacional de Oncolog&iacute;a y Radiobiolog&iacute;a.    La Habana, Cuba. </font>     <br>   <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><SUP>IV</SUP>Especialista    de I Grado en Oncolog&iacute;a. Asistente. Departamento de Radioterapia, Instituto    Nacional de Oncolog&iacute;a y Radiobiolog&iacute;a. La Habana, Cuba. </font>    <br>   <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><SUP>V</SUP>Ingeniero    en F&iacute;sica Nuclear. Departamento de Radioterapia, Instituto Nacional de    Oncolog&iacute;a y Radiobiolog&iacute;a. La Habana, Cuba. </font>     <br>   <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><SUP>VI</SUP>Doctor    en Ciencias T&eacute;cnicas. Ingeniero en F&iacute;sica Nuclear. Investigador    Auxiliar. Departamento de Radioterapia, Instituto Nacional de Oncolog&iacute;a    y Radiobiolog&iacute;a. La Habana, Cuba. </font>     <br>   <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><SUP>VII</SUP>Ingeniero    en F&iacute;sica Nuclear. Departamento de Radioterapia, Instituto Nacional de    Oncolog&iacute;a y Radiobiolog&iacute;a. La Habana, Cuba. </font>     ]]></body>
<body><![CDATA[<br>   <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><SUP>VIII</SUP>Doctor    en Ciencias T&eacute;cnicas. Ingeniero en F&iacute;sica Nuclear. Investigador    Agregado. Departamento de Radioterapia, Instituto Nacional de Oncolog&iacute;a    y Radiobiolog&iacute;a. La Habana, Cuba. </font>     <br>   <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><SUP>IX</SUP>Licenciado    en F&iacute;sica Nuclear. Departamento de Radioterapia, Instituto Nacional de    Oncolog&iacute;a y Radiobiolog&iacute;a. La Habana, Cuba. </font>    <br>   <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><SUP>X</SUP>Licenciado    en F&iacute;sica Nuclear. Departamento de Radioterapia. Instituto Nacional de    Oncolog&iacute;a y Radiobiolog&iacute;a. La Habana, Cuba. </font>      <P ALIGN="left">     <P ALIGN="left">    <br>         <br>         <br>         <br>  <hr size="1" noshade>     <P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>RESUMEN</strong></font>     ]]></body>
<body><![CDATA[<P ALIGN="left"><strong><font size="2" face="Verdana, Arial, Helvetica, sans-serif">INTRODUCCI&Oacute;N.</font></strong><font size="2" face="Verdana, Arial, Helvetica, sans-serif"> La radioterapia de intensidad modulada (IMRT) constituye una t&eacute;cnica    de alta precisi&oacute;n basada en la definici&oacute;n volum&eacute;trica tridimensional de la anatom&iacute;a del tumor y    de los &oacute;rganos cr&iacute;ticos o en riesgo. Con el objetivo de asegurar la posibilidad de aplicar la IMRT    en Cuba, en casos seleccionados de tumores en ni&ntilde;os y adolescentes, se instrument&oacute; un proyecto    de investigaci&oacute;n  cuyos resultados se documentan en este informe. </font>    <br>   <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><B>M&Eacute;TODOS</B>. Se realizaron las primeras irradiaciones con IMRT en ni&ntilde;os y adolescentes    cubanos, con edades entre 6 y 18 a&ntilde;os. La t&eacute;cnica empleada es la basada en aperturas geom&eacute;tricas    y optimizaci&oacute;n inversa. Las irradiaciones fueron realizadas con un acelerador lineal con fotones    de 6 MV, con colimador multil&aacute;minas. Las dosis de radiaciones administradas variaron seg&uacute;n el    tipo de tumor, y de acuerdo con las normas de radioterapia y la presencia de &oacute;rganos cr&iacute;ticos. Todos    los pacientes fueron evaluados semanalmente, con controles radiol&oacute;gicos mediante placas    portales electr&oacute;nicas. </font>       <br>   <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><B>RESULTADOS. </B>Los pacientes irradiados (5) ten&iacute;an los tumores siguientes: linfoma    no-Hodgking del seno maxilar (1), glioma del tallo cerebral (1), linfoma no-Hodgking abdominal    (1), condrosarcoma mesenquimatoso paramen&iacute;ngeo (1) y hemangiopericitoma paramen&iacute;ngeo (1).    Las dosis de irradiaci&oacute;n recibidas variaron entre 24  y 62 Gy. Fueron empleados entre 5 y 8    campos, con variaciones entre 10 y 20 segmentos. </font>       <br>   <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><B>CONCLUSIONES. </B> Se realizaron en Cuba las primeras irradiaciones con IMRT en ni&ntilde;os    y adolescentes, y se debe continuar extendiendo su empleo en aquellos casos donde su utilidad    sea mayor. </font>     <P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><B>Palabras clave</B>: Radioterapia de intensidad modulada,  IMRT, tumores, pediatr&iacute;a, Cuba.</font> <hr size="1" noshade>     <P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><strong>ABSTRACT</strong></font>     <P ALIGN="left"><strong><font size="2" face="Verdana, Arial, Helvetica, sans-serif">INTRODUCTION. </font></strong><font size="2" face="Verdana, Arial, Helvetica, sans-serif">The intensity modulated radiotherapy (IMRT) is a high performance    technique based on the three-dimensional volumetric definition of tumor anatomy and of critical organs    or at risk. To assure the possibility to apply the IMRT in Cuba in selected cases of tumors in    children and adolescents, authors designed a research project whose results are documented in    present report.    </font>       <br>   <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><B>METHODS</B>. The first irradiations with IMRT in Cuban children and adolescents aged between    6 -18 were carried out. The technique used is that based on the geometric openings and    inverse optimization. Irradiations were applied using a linear accelerator with 6 MV photons, with    multileaf collimator. Doses administered varied according to the type of tumor, the radiotherapy    standards and the presence of critical organs. All patients were assessed weekly with radiologic    controls using electronic portal plates.  </font>       <br>   <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><B>RESULTS</B>. Irradiated patients (5) had the following tumors: non-Hodgkin lymphoma of    maxillary sinus (1), brain stem glioma (1), non-Hodgkin abdominal lymphoma (1),    parameningeal mesenchymatous chondrosarcoma (1) and parameningeal hemangiopericytoma (1). Doses    of radiation applied varied between 24 and 62 Gy. Between 5 and 8 fields were used with    variations among 10 and 20 segments.  </font>       <br>   <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><B>CONCLUSIONS</B>.  In Cuba the first irradiations with IMRT in children and adolescents and    its use must to be spreading to those cases where its usefulness is greater.    </font>     ]]></body>
<body><![CDATA[<P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif"><B>Key words</B>: Modulated intensity radiotherapy, MIRT, tumor, Pediatrics, Cuba.</font> <hr size="1" noshade>     <P ALIGN="left">    <br>         <br>         <br>         <br>         <br>   <font size="3" face="Verdana, Arial, Helvetica, sans-serif"><B>INTRODUCCI&Oacute;N</B></font>     <P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">La radioterapia de intensidad modulada (IMRT, del ingl&eacute;s <I>intensity modulated radiotherapy</I>) constituye una t&eacute;cnica de alta precisi&oacute;n basada en la definici&oacute;n volum&eacute;trica tridimensional de    la anatom&iacute;a del tumor y de los &oacute;rganos cr&iacute;ticos o en riesgo. </font>     <P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">La reconstrucci&oacute;n digital de estos vol&uacute;menes es posible mediante la adquisici&oacute;n de una serie    de im&aacute;genes de la secci&oacute;n transversal de la regi&oacute;n por irradiar, adquiridos mediante tomograf&iacute;a axial computarizada (TAC) o resonancia magn&eacute;tica (RM). Sus ventajas son: permite optimizar la   geometr&iacute;a de los tratamientos seleccionando el n&uacute;mero y los &aacute;ngulos de entrada de los campos  y de los segmentos de cada campo, conformando con precisi&oacute;n las dimensiones de los blancos,  as&iacute; como variando o modulando la intensidad  de la aplicaci&oacute;n de la dosis en el tiempo. El  resultado es la dosis prescripta puede ser aplicada con uniformidad en el volumen blanco. A su vez  protege los tejidos sanos vecinos y ha hecho posible incrementar las dosis de irradiaci&oacute;n  aplicadas.<sup>1-7</sup> Campos de irradiaci&oacute;n de diferentes intensidades son empleados dependiendo del tumor o  los &oacute;rganos en riesgo localizados en las diferentes &aacute;reas incluidas en el rayo; de esta forma  la distribuci&oacute;n de la dosis puede adaptarse a geometr&iacute;as irregulares. </font>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Existen diferentes soluciones t&eacute;cnicas para poder realizar estos requerimientos: una soluci&oacute;n    es la IMRT segmentada con colimadores multil&aacute;minas, donde campos irregulares se crean por    una sumatoria de peque&ntilde;os campos o segmentos resultando en una aplicaci&oacute;n de dosis en    &#171;pulsos&#187;.<sup>1</sup> Otra soluci&oacute;n para modular la intensidad es el movimiento din&aacute;mico de las l&aacute;minas de    los colimadores durante la aplicaci&oacute;n de la    irradiaci&oacute;n,<sup>8</sup> y una tercera t&eacute;cnica es la    tomoterapia helicoidal.<sup>9 </sup>Es muy &uacute;til en el tratamiento de lesiones irregulares, blancos multic&eacute;ntricos    (como sucede en la cabeza y el cuello), blancos intracraneales (tumores del sistema nervioso    central), para el control de la calidad en cuanto a indicaciones y efectividad del tratamiento, y    posibles efectos o complicaciones. </font>     ]]></body>
<body><![CDATA[<p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Mientras que la IMRT ha sido ampliamente empleada en la irradiaci&oacute;n de tumores en los    pacientes adultos, su empleo ha sido m&aacute;s cauteloso en los ni&ntilde;os y adolescentes. Entre los motivos se    ha se&ntilde;alado el incremento en el tiempo en cada fracci&oacute;n, la necesidad de una exacta    inmovilizaci&oacute;n y los posibles riesgos de un segundo tumor inducido por cambios en la dosis    integral.<sup>7,10-16</sup> </font>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Se instrument&oacute; un Proyecto de Investigaci&oacute;n con el prop&oacute;sito de  asegurar la posibilidad de    realizar IMRT en Cuba, en casos seleccionados de tumores de ni&ntilde;os y adolescentes. Se presentan    los primeros 5 pacientes ni&ntilde;os y adolescentes, con edades entre 6 y 18 a&ntilde;os, tratados en nuestro    pa&iacute;s con IMRT a partir de 2009. </font>     <p align="left">    <br>         <br>   <font size="3" face="Verdana, Arial, Helvetica, sans-serif"><b>M&Eacute;TODOS</b></font>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Se instrument&oacute; y se realizaron en Cuba las primeras irradiaciones con IMRT en ni&ntilde;os y    adolescentes con edades entre 6 y 18 a&ntilde;os: 1 paciente con linfoma no Hodgkin recidivante de seno maxilar,    1 paciente con glioma del tallo cerebral, 1 paciente con linfoma no-Hodgkin abdominal, 1    paciente con condrosarcoma mesenquimatoso paramen&iacute;ngeo y 1 paciente con    hemangiopericitoma paramen&iacute;ngeo. </font>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Las dosis  de irradiaci&oacute;n recibidas variaron entre 24  y 68 Gy. Fueron empleados en cada paciente    entre 5 y  8 campos de irradiaci&oacute;n con variaciones entre 10 y 20 segmentos.  Las caracter&iacute;sticas    de estos pacientes se muestran en el <a href="#tabla1">cuadro</a>. </font>     <p align="center"><a name="tabla1"></a>  <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><b>Cuadro.</b> Caracter&iacute;sticas de los pacientes </font>     <div align="left">   <table border="1" align="center" cellpadding="0" cellspacing="3">     <tr>       <td width="32" valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Caso</font></p></td>       <td width="76" valign="top">    ]]></body>
<body><![CDATA[<p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Edad</font></p></td>       <td width="134" valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Diagn&oacute;stico</font></p></td>       <td width="108" valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Localizaci&oacute;n</font></p></td>       <td width="62" valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Dosis</font></p></td>       <td width="53" valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Campos</font></p></td>       <td width="78" valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Fracciones</font></p></td>     </tr>     <tr>       <td valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1</font></p></td>       <td valign="top">    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18 a&ntilde;os</font></p></td>       <td valign="top">    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Linfoma no Hodgkin</font></p></td>       <td valign="top">    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Seno maxilar</font></p></td>       <td valign="top">    ]]></body>
<body><![CDATA[<p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30 Gy</font></p></td>       <td valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7</font></p></td>       <td valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15</font></p></td>     </tr>     <tr>       <td valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2</font></p></td>       <td valign="top">    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6 a&ntilde;os</font></p></td>       <td valign="top">    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Glioma&nbsp;&nbsp; </font></p></td>       <td valign="top">    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Tallo cerebral</font></p></td>       <td valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">59,4 Gy</font></p></td>       <td valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6</font></p></td>       <td valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33</font></p></td>     </tr>     <tr>       <td valign="top">    ]]></body>
<body><![CDATA[<p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3</font></p></td>       <td valign="top">    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8 a&ntilde;os</font></p></td>       <td valign="top">    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Linfoma no Hodgkin</font></p></td>       <td valign="top">    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Abdomen</font></p></td>       <td valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12 Gy</font></p></td>       <td valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5</font></p></td>       <td valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9</font></p></td>     </tr>     <tr>       <td valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4</font></p></td>       <td valign="top">    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15 a&ntilde;os</font></p></td>       <td valign="top">    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Condrosarcoma</font></p></td>       <td valign="top">    ]]></body>
<body><![CDATA[<p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Paramen&iacute;ngea</font></p></td>       <td valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">68 Gy</font></p></td>       <td valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6</font></p></td>       <td valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">34</font></p></td>     </tr>     <tr>       <td valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5</font></p></td>       <td valign="top">    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16 a&ntilde;os</font></p></td>       <td valign="top">    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Hemangiopericitoma</font></p></td>       <td valign="top">    <p><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Paramen&iacute;ngea</font></p></td>       <td valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">59,4 Gy</font></p></td>       <td valign="top">    <p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8</font></p></td>       <td valign="top">    ]]></body>
<body><![CDATA[<p align="center"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33</font></p></td>     </tr>   </table> </div>     <p align="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">    <br>   La planificaci&oacute;n del tratamiento radiante fue realizada en los sistemas de planificaci&oacute;n    de tratamiento (TPS, por sus siglas en ingl&eacute;s) Elekta PrecisePlan v2.11 y 2.16. La t&eacute;cnica de    IMRT empleada es la basada en aperturas geom&eacute;tricas y optimizaci&oacute;n inversa. En esta t&eacute;cnica una    vez definidos el n&uacute;mero y &aacute;ngulos de entrada de los campos de tratamiento, se pasa a construir    los segmentos necesarios para modular la intensidad del haz de cada campo en cuesti&oacute;n. Los    segmentos se crean mediante operaciones de adici&oacute;n-substracci&oacute;n de los vol&uacute;menes blancos y &oacute;rganos    en riesgo. Los segmentos son posteriormente validados y corregidos, de manera que tengan    una racionalidad en el aporte a la dosis modulada. El &uacute;ltimo paso es la optimizaci&oacute;n inversa del    plan partiendo de los objetivos y restricciones que definen la prescripci&oacute;n del tratamiento en    cuesti&oacute;n y las penalidades asignadas a cada uno de ellos. El resultado de la  distribuci&oacute;n de dosis es    evaluado por el dosimetrista o el f&iacute;sico a cargo, y se realizan los cambios pertinentes para alcanzar  los objetivos propuestos en la planificaci&oacute;n. </font></p>     <P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">En los pacientes con lesiones localizadas en la cabeza y el cuello fueron empleadas    m&aacute;scaras termopl&aacute;sticas como elemento de fijaci&oacute;n. Las irradiaciones fueron realizadas con un    acelerador lineal con fotones de 6 MV, con colimador multil&aacute;minas. </font>     <P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Las dosis de radiaciones administradas variaron seg&uacute;n el tipo de tumor y de acuerdo con    las Normas de Radioterapia y la presencia de &oacute;rganos cr&iacute;ticos. </font>     <P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Todos los pacientes fueron evaluados semanalmente, con realizaci&oacute;n de controles    radiol&oacute;gicos por medio de placas  portales electr&oacute;nicas. </font>     <P ALIGN="left">    <br>         <br>   <font size="3" face="Verdana, Arial, Helvetica, sans-serif"><B>RESULTADOS</B></font>     <P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Fueron irradiados mediante la t&eacute;cnica de IMRT 5 pacientes ni&ntilde;os o adolescentes con    tumores malignos,  los primeros tratados con IMRT en Cuba. </font>     ]]></body>
<body><![CDATA[<P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">El paciente n&uacute;m. 1, con diagn&oacute;stico de linfoma no Hodgkin del seno maxilar derecho, hab&iacute;a    sido irradiado localmente un a&ntilde;o antes, adem&aacute;s de haber recibido tratamiento con quimioterapia,    tras la que present&oacute; una reca&iacute;da local por lo que se decidi&oacute; la irradiaci&oacute;n. Se mantiene en    remisi&oacute;n completa 16 meses tras la IMRT. </font>     <P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">El paciente n&uacute;m. 3 padec&iacute;a de un linfoma abdominal no hodgkiniano altamente agresivo, que    a pesar de la quimioterapia recibida continuaba creciendo. En el curso de la irradiaci&oacute;n el    tumor sigui&oacute; aumentando de volumen y aparecieron nuevas lesiones multic&eacute;ntricas. Se produjo    un empeoramiento del estado general, por lo que se decidi&oacute; dar por terminada la irradiaci&oacute;n y    solo recibi&oacute; 12 Gy. Falleci&oacute; a los pocos d&iacute;as. </font>     <P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Los pacientes n&uacute;m. 4 y 5 hab&iacute;an recibido tratamiento quir&uacute;rgico antes de la irradiaci&oacute;n, y    quedaban restos de tumor en los m&aacute;rgenes quir&uacute;rgicos. </font>     <P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Los 4 pacientes con histolog&iacute;as no linfomatosas presentaron episodios de radiodermitis de  grado II  o III, as&iacute; como radiomucositis de grado I y II, por lo cual fue necesario interrumpir  temporalmente los tratamientos, especialmente en la paciente n&uacute;m. 4. Se debe se&ntilde;alar que los pacientes de  lesiones paramen&iacute;ngeas recibieron quimioterapia concurrente. A pesar del mal pron&oacute;stico de estos  pacientes, se mantienen vivos y controlados, entre 3 y 8 meses de terminada la irradiaci&oacute;n. </font>     <P ALIGN="left">    <br>         <br>   <font size="3" face="Verdana, Arial, Helvetica, sans-serif"><B>DISCUSI&Oacute;N</B></font>     <P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">Presentamos un grupo de 5 pacientes ni&ntilde;os y adolescentes, los primeros tratados en Cuba    empleando IMRT. </font>     <P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">La IMRT es un m&eacute;todo de alta precisi&oacute;n en radioterapia que ha permitido alcanzar avances    notables en la conformaci&oacute;n del blanco de irradiaci&oacute;n, escalada de la dosis y protecci&oacute;n en los &oacute;rganos    en riesgo situados en la cercan&iacute;a del volumen  blanco. Campos de irradiaci&oacute;n de diferentes    intensidades son empleados dependiendo del tumor o los &oacute;rganos en riesgo localizados en las diferentes    &aacute;reas incluidas en el rayo, y de esta forma la distribuci&oacute;n de la dosis puede adaptarse a    geometr&iacute;as irregulares. </font>     <P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">En contraste con el gran n&uacute;mero de informes acerca del empleo de IMRT en el tratamiento de    los tumores malignos en los pacientes adultos a partir del decenio de 1990, el numero de ni&ntilde;os    es relativamente pobre, y aparecen a partir de esta    d&eacute;cada.<SUP>10,17-32</SUP> En algunos de estos informes    hablan de la posibilidad de respetar o solo alcanzar dosis m&iacute;nimas en estructuras normales vecinas,    e incluso del decrecimiento de la morbilidad relacionada con la aplicaci&oacute;n de la irradiaci&oacute;n;    por ejemplo,  posible reducci&oacute;n de la ototoxicidad al reducirse la dosis recibida en la regi&oacute;n    coclear durante la irradiaci&oacute;n de los tumores del sistema nervioso central, de los dosis en otros    &oacute;rganos intracraneales, protecci&oacute;n de las estructuras de las &oacute;rbitas en el caso de los    retinoblastomas localizados intraocularmente y con el potencial de reducir la deformidad producida por    un crecimiento &oacute;seo irregular, xerostom&iacute;a por atrofia de las gl&aacute;ndulas salivales, mucositis y    disfagia en pacientes con tumores localizados a la cabeza y el    cuello.<SUP>14, 17-24, 32, 33</SUP> </font>     ]]></body>
<body><![CDATA[<P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">En las discusiones referentes al empleo de la IMRT en los c&aacute;nceres pedi&aacute;tricos se se&ntilde;ala que    las ventajas se alcanzan al costo de aumentar las bajas dosis integrales fuera del    blanco.<SUP>7, 10</SUP> Sin embargo,  existen informes de que no hay un incremento de las dosis recibidas en &oacute;rganos como las    mamas o los test&iacute;culos en ni&ntilde;os tratados con IMRT, comparados con un grupo de pacientes tratados    con irradiaci&oacute;n convencional por tumores craneales o    abdominales.<SUP>15</SUP> Entre los factores que    se consideran para tener en cuenta  en el tratamiento de los ni&ntilde;os est&aacute;n los relativamente    grandes vol&uacute;menes que recibir&iacute;an peque&ntilde;as dosis de irradiaci&oacute;n que pueden no ocasionar    morbilidades inmediatas pero que ser&iacute;an potencialmente cancer&iacute;genas, la mayor sensibilidad a tumores    inducidos por radiaciones y la susceptibilidad gen&eacute;tica ligada a las mutaciones    germinales.<SUP>13,14, 16,34-37</SUP> No obstante,  a pesar de que existen trabajos acerca de pacientes irradiados con IMRT de varios    a&ntilde;os de    evoluci&oacute;n,<SUP>10,16,19,37</SUP> no aparecen informes de la aparici&oacute;n de segundos tumores inducidos    por radiaciones. </font>     <P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">En conclusi&oacute;n, se demuestra la  posibilidad de implementar y realizar la irradiaci&oacute;n de    intensidad modulada (IMRT) en nuestro medio. En este caso el grupo escogido eran pacientes en    situaciones dif&iacute;ciles y de mal pron&oacute;stico  (reca&iacute;da en un &aacute;rea previamente irradiada, lesiones de dif&iacute;cil    acceso en la cabeza y el cuello, tumor que no respond&iacute;a a la quimioterapia ni tampoco a la    radioterapia). El empleo de esta t&eacute;cnica requerir&aacute; de posterior implementaci&oacute;n de la selecci&oacute;n de los casos,    con un cuidadoso seguimiento de estos, buscando complicaciones tard&iacute;as, especialmente segundos tumores. Reservada para lesiones irregulares de dif&iacute;cil acceso, la IMRT puede resultar de  gran utilidad para su tratamiento. </font>     <P ALIGN="left">    <br>         <br>   <font size="3" face="Verdana, Arial, Helvetica, sans-serif"><B>REFERENCIAS BIBLIOGR&Aacute;FICAS</B></font>     <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">1.     Intensity Modulated Radiation Therapy Collaborative Working Group: IMRT: current    status and issues of interest. Int J Radiat Oncol Biol Phys. 2001;51:880-914. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">2.     Nutting C, Dearnaley DP, Webb S. IMRT: a clinical review. Br J Radiol. 2000;73:459-69. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">3.     Pirzcall A, Carol M, Lohr F, Hoss A, Wannenmacher M, Debus J. Comparison of IMRT    with conventional conformal radiotherapy for complex-shaped tumors. Int J Radiat Oncol    Biol Phys. 2000;48:1371-80. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">4.     Zhen W, Thompson RB, Enke CA. IMRT: the radiation oncologist perspective. Med    Dosim. 2002;27:155-9. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">5.     Wolden SL, Wexler LH, Krauss DH, Laquaglia MP, Lis E, Meyers PA. IMRT for    head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys. 2005;61:1432-8. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">6.     Veldeman L, Madani I, Hulstaert F, De Meerler G, Mareel M, De Neve W. Evidence    behind use of IMRT: a systematic review of comparative clinical studies. Lancet Oncol.    2008;9:367-75. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">7.     Welsh JS, Limmer JP, Howard SP, Diamond D, Harari PM. Precautions in the use of    intensity-modulated radiation therapy. Thecnol Cancer Res Treat. 2005;4:203-10. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">8.     Boyer A, Xing L, Luxton G, Chen Y, Ma C. IMRT by dynamic  MLC. In: Schlegel W,    Borfeld T. The use of computers in Radiation Therapy XII International conference. , Berlin:    Springer; 2000. Pp. 160-3. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">9.     Makie TR, Balog J, Ruchala K, Shepard D, Aldridge S, Fitchard E, et al.    Tomotherapy. Semin Radiat Oncol. 1999;9:108-17. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">10.     Sterzing F, Stoiber EM,Nill S, Bauer H, Huber P, Debus J, <I>et al</I>. IMRT in the treatment of children and adolescents- a single institution&#180;s experience and review of the literature.    BMC Radiation Oncology. 2009;4:37. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">11.     Santiago R, Gladstein E. Pros and cons of IMRT. What been swept under the rough.     In: Munt AJ and Roeske JC editors. Intensity Modulated Radiation Therapy: A Clinical    Perspective. Hamilton: BC Decker INC.; 2005. Pp.628-37. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">12.     Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int    J Radiat Oncol Biol Phys. 2003;56:83-8. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">13.     Hall EJ. IMRT, protons and the risk of second cancer. Int J Radiat Oncol Bio Phys.    2006;65:1-7. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">14.     Kry SF, Salehpour M, Followill DS, Stoval M, Kuban DA, White RA, <I>et al.</I> The calculated risk of fatal secondary malignancies from IMRT. Int J Radiat Oncol Biol. Phys.    2005;62:1195-1203. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">15.     Koshy M, Paulino AC, Marcus RB Jr, Ting JY, Whitaker D, Davis LW. Extra-target doses    in children receiving multileaf collimator (MLC) based IMRT. Pediatr Blood Cancer,    2004;42:626-30. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">16.     Nguyen F, Rubino C, Guerin S, Diallo, Samand A, Hawkins M, <I>et al.</I> Risk of a second malignant neoplasm after cancer in childhood treated with radiotherapy; correlations with    the integral dose restricted to the irradiated fields. Int J Radiat Oncol Biol Phys. 2008;70:908-15. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">17.     Bhatnagar A, Deutsch M. The role for IMRT in pediatric population. Thecnol Cancer    Res Treat. 2006;5:591-6. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">18.     Penagaricano JA, Papanikolaou N, Yan Y, Ratanatharathorn. Application of IMRT for    pediatric malignancies. Med Dosim. 2004;29:247-53. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">19.     Paulino AC, Skwarchuk M. IMRT in the treatment of children. Med Dosim.  2002;27:115-20. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">20.     The BS, May WY, Grant WH 3erd, Chiu JK, Lu HH, Carpenter LS, <I>et al.</I> Intensity modulated radiotherapy (IMRT) decreases treatment-related morbidity and potentially enhances    tumor control. Cancer Invest. 2002;20:437-51. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">21.     Huang E, Teh BS, Strother DR, Davis QG,Chiu JK, Lu HH, <I>et al.</I> IMRT for pediatric medulloblastoma: early report on the reduction of ototoxicity. Int J Radiat Oncol Biol    Phys. 2002;52:599-605. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">22.     Jain N, Krull KR, Brouwers P, Chintagumpala MM, Woo SY. Neuropsychological    outcome following IMRT for pediatric medulloblastoma. Pediatr Blood Cancer. 2008;51:275-9. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">23.     Krasin MJ, Crawford BT, Zhu Y, Evans ES, Sontag MR, Kun LE, Merchant TE. IMRT    for children with intraocular retinoblastoma: potential sparing of the bony orbit.   Clin Oncol    (R Coll Radiol). 2004;16:215-22. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">24.     Schoeder TM, Chintagumpala M, Okcu MF, Chiu JK, Teh BS,Woo SY, <I>et al</I>. IMRT in childhood ependymoma. Int J Radiat Oncol Biol Phys. 2008;71:987993. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">25.     McDonald MW, Esiashvili N, George BA, Katzsenstein HM, Olson TA, Rapkin LB, <I>et al.</I> IMRT with the use of cone-down boost for pediatric head-and-neck carcinoma. Int J    Radiat Oncol Biol Phys. 2008;72:884-91. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">26.     Curtis AE,Okcu MF, Chintagumpala, Teh BS, Paulino AC. Local control after IMRT    for Head-and-Neck carcinoma. Int J Radiat Oncol Biol Phys. 2008;73:173-7. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">27.     Combs SE, Benisch W, Kulozik AE, Huber PE, Debus J, Schultz-Ertner D. IMRT    and fractionated Stereotactic Radiotherapy (FSRT) for children with    head-and-neck-rhabdomyosarcoma. BMC Cancer.  2007;7:177. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">28.     Laskar S, Bahl G, Muckaden M, Pai SK, Gupta T, Banavali S, <I>et al.</I> Nasopharyngeal carcinoma in children: comparison of conventional and IMRT. Int J Radiat Oncol Biol Phys.    2008;72:728-36. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">29.     Kuppersmith RB, Teh BS, Donovan DT, May WY, Chiu JK, Woo SK, <I>et al</I> The use of intensity modulated radiotherapy for the treatment of extensive and recurrent juvenile    angiofibroma. Int J Pediatr Othorhinolaryngol.  2000;52:261-8. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">30.     Parker W, Filion E, Roberge D, Freeman CR. IMRT for craniospinal irradiation: target    volume considerations, dose constrains and competing risk. Int J Radiat Oncol Biol Phys.    2007;69:251-7. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">31.     Rembielak A, Woo TC. IMRT for the treatment of pediatric cancer patients. Nat Clin    Pract Oncol. 2005;2:211-7. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">32.     Beltran CH, Naik J, Merchant Th. Dosimetric effect of setup motion and target    volume margin reduction in pediatric ependymoma. Radiother Oncol. 2010;96:216-22. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">33.     Penagaricano JA, Tan Y, Corry P, Moros E, Ratanatharathorn V. Retrospective evaluation    of pediatric cranio-spinal axis irradiation plans with the Hi-ART tomotherapy system.    Thecnol Cancer Res Treat. 2007;6:355-60. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">34.     Verellen D, Vanhaver F. Risk assessment of radiation-induced malignancies based on    whole-body equivalent dose estimates for IMRT treatment in the head and neck region.    Radiother Oncol. 1999;53:199-203. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">35.     Hall EJ. The inaugural Frank Ellis Lecture-Iatrogenic cancer: the impact of    intensity-modulated radiotherapy. Clin Oncol (R Coll Radiol). 2006;18:277-82. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">36.     Lin HM, Teitell MA. Second malignancy after treatment of pediatric Hodgkin disease.    J Pediatr Hematol Oncol. 2005;27:28-36. </font>    <!-- ref --><P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">37.     Woo SY. Pediatric Tumors: overview. In: Munt AJ and Roeske JC, editors. Intensity    Modulated Radiation Therapy: A Clinical Perspective. Hamilton: BC Decker INC.; 2005. Pp. 573-9. </font>    <P ALIGN="left"><font size="2" face="Verdana, Arial, Helvetica, sans-serif">    <br>         <br>         <br>         <br>   Recibido: 28 de octubre de 2010. </font>       <br>   <font size="2" face="Verdana, Arial, Helvetica, sans-serif">Aprobado: 16 de diciembre de 2010.</font>       <br>       <br>       ]]></body>
<body><![CDATA[<br>       <br>       <br>   <font size="2" face="Verdana, Arial, Helvetica, sans-serif"><I>Jos&eacute; Alert Silva. </I>Departamento de Radioterapia, Instituto Nacional de Oncolog&iacute;a y    Radiobiolog&iacute;a. Calle 29 y F, El Vedado. La Habana, Cuba. </font>       <br>   <font size="2" face="Verdana, Arial, Helvetica, sans-serif">Correo electr&oacute;nico: <a href="mailto:jalert@infomed.sld.cu">jalert@infomed.sld.cu</a></font>      ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<article-title xml:lang="en"><![CDATA[Intensity Modulated Radiation Therapy Collaborative Working Group: IMRT: current status and issues of interest]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2001</year>
<volume>51</volume>
<page-range>880-914</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nutting]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Dearnaley]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Webb]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[IMRT: a clinical review]]></article-title>
<source><![CDATA[Br J Radiol.]]></source>
<year>2000</year>
<volume>73</volume>
<page-range>459-69</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pirzcall]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carol]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lohr]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hoss]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wannenmacher]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Debus]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Comparison of IMRT with conventional conformal radiotherapy for complex-shaped tumors]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2000</year>
<volume>48</volume>
<page-range>1371-80</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhen]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Thompson]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Enke]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[IMRT: the radiation oncologist perspective]]></article-title>
<source><![CDATA[Med Dosim.]]></source>
<year>2002</year>
<volume>27</volume>
<page-range>155-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wolden]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Wexler]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Krauss]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Laquaglia]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
<name>
<surname><![CDATA[Lis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Meyers]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[IMRT for head-and-neck rhabdomyosarcoma]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2005</year>
<volume>61</volume>
<page-range>1432-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Veldeman]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Madani]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Hulstaert]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[De Meerler]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Mareel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[De Neve]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Evidence behind use of IMRT: a systematic review of comparative clinical studies]]></article-title>
<source><![CDATA[Lancet Oncol.]]></source>
<year>2008</year>
<volume>9</volume>
<page-range>367-75</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Welsh]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Limmer]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Howard]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
<name>
<surname><![CDATA[Diamond]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Harari]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Precautions in the use of intensity-modulated radiation therapy]]></article-title>
<source><![CDATA[Thecnol Cancer Res Treat.]]></source>
<year>2005</year>
<volume>4</volume>
<page-range>203-10</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boyer]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Xing]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Luxton]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ma]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[IMRT by dynamic MLC]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Schlegel]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Borfeld]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[The use of computers in Radiation Therapy XII International conference]]></source>
<year>2000</year>
<page-range>Pp. 160-3</page-range><publisher-loc><![CDATA[Berlin ]]></publisher-loc>
<publisher-name><![CDATA[Springer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Makie]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Balog]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ruchala]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Shepard]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Aldridge]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fitchard]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Tomotherapy]]></article-title>
<source><![CDATA[Semin Radiat Oncol.]]></source>
<year>1999</year>
<volume>9</volume>
<page-range>108-17</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sterzing]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Stoiber]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Nill]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bauer]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Huber]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Debus]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[IMRT in the treatment of children and adolescents- a single institution´s experience and review of the literature]]></article-title>
<source><![CDATA[BMC Radiation Oncology.]]></source>
<year>2009</year>
<volume>4</volume>
<page-range>37</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Santiago]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gladstein]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Pros and cons of IMRT: What been swept under the rough]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Munt]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Roeske]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[Intensity Modulated Radiation Therapy: A Clinical Perspective]]></source>
<year>2005</year>
<page-range>Pp.628-37</page-range><publisher-loc><![CDATA[Hamilton ]]></publisher-loc>
<publisher-name><![CDATA[BC Decker INC]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wuu]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Radiation-induced second cancers: the impact of 3D-CRT and IMRT]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2003</year>
<volume>56</volume>
<page-range>83-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[IMRT, protons and the risk of second cancer]]></article-title>
<source><![CDATA[Int J Radiat Oncol Bio Phys]]></source>
<year>2006</year>
<volume>65</volume>
<page-range>1-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kry]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Salehpour]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Followill]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Stoval]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kuban]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The calculated risk of fatal secondary malignancies from IMRT]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol. Phys]]></source>
<year>2005</year>
<volume>62</volume>
<page-range>1195-1203</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koshy]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Paulino]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Marcus]]></surname>
<given-names><![CDATA[RB Jr]]></given-names>
</name>
<name>
<surname><![CDATA[Ting]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Whitaker]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[LW]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Extra-target doses in children receiving multileaf collimator (MLC) based IMRT]]></article-title>
<source><![CDATA[Pediatr Blood Cancer,]]></source>
<year>2004</year>
<volume>42</volume>
<page-range>626-30</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rubino]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Guerin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Diallo]]></surname>
</name>
<name>
<surname><![CDATA[Samand]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hawkins]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Risk of a second malignant neoplasm after cancer in childhood treated with radiotherapy; correlations with the integral dose restricted to the irradiated fields]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2008</year>
<volume>70</volume>
<page-range>908-15</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhatnagar]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Deutsch]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The role for IMRT in pediatric population]]></article-title>
<source><![CDATA[Thecnol Cancer Res Treat.]]></source>
<year>2006</year>
<volume>5</volume>
<page-range>591-6</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Penagaricano]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Papanikolaou]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Ratanatharathorn]]></surname>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Application of IMRT for pediatric malignancies]]></article-title>
<source><![CDATA[Med Dosim.]]></source>
<year>2004</year>
<volume>29</volume>
<page-range>247-53</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paulino]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Skwarchuk]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[IMRT in the treatment of children]]></article-title>
<source><![CDATA[Med Dosim.]]></source>
<year>2002</year>
<volume>27</volume>
<page-range>115-20</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[The]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[May]]></surname>
<given-names><![CDATA[WY]]></given-names>
</name>
<name>
<surname><![CDATA[Grant]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Chiu]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
<name>
<surname><![CDATA[Carpenter]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Intensity modulated radiotherapy (IMRT) decreases treatment-related morbidity and potentially enhances tumor control]]></article-title>
<source><![CDATA[Cancer Invest.]]></source>
<year>2002</year>
<volume>20</volume>
<page-range>437-51</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Teh]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Strother]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Davis]]></surname>
<given-names><![CDATA[QG]]></given-names>
</name>
<name>
<surname><![CDATA[Chiu]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[HH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[IMRT for pediatric medulloblastoma: early report on the reduction of ototoxicity]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2002</year>
<volume>52</volume>
<page-range>599-605</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Krull]]></surname>
<given-names><![CDATA[KR]]></given-names>
</name>
<name>
<surname><![CDATA[Brouwers]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Chintagumpala]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Woo]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Neuropsychological outcome following IMRT for pediatric medulloblastoma]]></article-title>
<source><![CDATA[Pediatr Blood Cancer.]]></source>
<year>2008</year>
<volume>51</volume>
<page-range>275-9</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krasin]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[BT]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[ES]]></given-names>
</name>
<name>
<surname><![CDATA[Sontag]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Kun]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
<name>
<surname><![CDATA[Merchant]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[IMRT for children with intraocular retinoblastoma: potential sparing of the bony orbit]]></article-title>
<source><![CDATA[Clin Oncol (R Coll Radiol).]]></source>
<year>2004</year>
<volume>16</volume>
<page-range>215-22</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schoeder]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Chintagumpala]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Okcu]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Chiu]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Teh]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Woo]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[IMRT in childhood ependymoma]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2008</year>
<volume>71</volume>
<page-range>987993</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McDonald]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Esiashvili]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[George]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Katzsenstein]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Olson]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Rapkin]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[IMRT with the use of cone-down boost for pediatric head-and-neck carcinoma]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2008</year>
<volume>72</volume>
<page-range>884-91</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Curtis]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Okcu]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Chintagumpala]]></surname>
</name>
<name>
<surname><![CDATA[Teh]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Paulino]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Local control after IMRT for Head-and-Neck carcinoma]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2008</year>
<volume>73</volume>
<page-range>173-7</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Combs]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Benisch]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Kulozik]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Huber]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
<name>
<surname><![CDATA[Debus]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Schultz-Ertner]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[IMRT and fractionated Stereotactic Radiotherapy (FSRT) for children with head-and-neck-rhabdomyosarcoma]]></article-title>
<source><![CDATA[BMC Cancer.]]></source>
<year>2007</year>
<volume>7</volume>
<page-range>177</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Laskar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bahl]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Muckaden]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pai]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Gupta]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Banavali]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Nasopharyngeal carcinoma in children: comparison of conventional and IMRT]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2008</year>
<volume>72</volume>
<page-range>728-36</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuppersmith]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Teh]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Donovan]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
<name>
<surname><![CDATA[May]]></surname>
<given-names><![CDATA[WY]]></given-names>
</name>
<name>
<surname><![CDATA[Chiu]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Woo]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The use of intensity modulated radiotherapy for the treatment of extensive and recurrent juvenile angiofibroma]]></article-title>
<source><![CDATA[Int J Pediatr Othorhinolaryngol.]]></source>
<year>2000</year>
<volume>52</volume>
<page-range>261-8</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Filion]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Roberge]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Freeman]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[IMRT for craniospinal irradiation: target volume considerations, dose constrains and competing risk]]></article-title>
<source><![CDATA[Int J Radiat Oncol Biol Phys]]></source>
<year>2007</year>
<volume>69</volume>
<page-range>251-7</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rembielak]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Woo]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[IMRT for the treatment of pediatric cancer patients]]></article-title>
<source><![CDATA[Nat Clin Pract Oncol.]]></source>
<year>2005</year>
<volume>2</volume>
<page-range>211-7</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beltran]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Naik]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Merchant]]></surname>
<given-names><![CDATA[Th]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Dosimetric effect of setup motion and target volume margin reduction in pediatric ependymoma]]></article-title>
<source><![CDATA[Radiother Oncol.]]></source>
<year>2010</year>
<volume>96</volume>
<page-range>216-22</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Penagaricano]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Corry]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Moros]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Ratanatharathorn]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Retrospective evaluation of pediatric cranio-spinal axis irradiation plans with the Hi-ART tomotherapy system]]></article-title>
<source><![CDATA[Thecnol Cancer Res Treat.]]></source>
<year>2007</year>
<volume>6</volume>
<page-range>355-60</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verellen]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Vanhaver]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Risk assessment of radiation-induced malignancies based on whole-body equivalent dose estimates for IMRT treatment in the head and neck region]]></article-title>
<source><![CDATA[Radiother Oncol.]]></source>
<year>1999</year>
<volume>53</volume>
<page-range>199-203</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The inaugural Frank Ellis Lecture-Iatrogenic cancer: the impact of intensity-modulated radiotherapy]]></article-title>
<source><![CDATA[Clin Oncol (R Coll Radiol).]]></source>
<year>2006</year>
<volume>18</volume>
<page-range>277-82</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Teitell]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Second malignancy after treatment of pediatric Hodgkin disease]]></article-title>
<source><![CDATA[J Pediatr Hematol Oncol.]]></source>
<year>2005</year>
<volume>27</volume>
<page-range>28-36</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Woo]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Pediatric Tumors: overview]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Munt]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Roeske]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[Intensity Modulated Radiation Therapy: A Clinical Perspective]]></source>
<year>2005</year>
<page-range>Pp. 573-9</page-range><publisher-loc><![CDATA[Hamilton ]]></publisher-loc>
<publisher-name><![CDATA[BC Decker INC]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
